Clinical trials: Severe Psoriasis
Chronic Plaque Psoriasis
Chronic Plaque Psoriasis (Ps) Registry
The purpose of this study is to evaluate the long-term safety of Humira® in Adult Patients with Chronic Plaque Psoriasis (Ps).
- Trial name
- NCT00799877
- Where
- 339 sites in United States, Austria and 12 more
- Volunteers
- 6,065 people
- Sponsor
- AbbVie
Plaque Psoriasis
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.
- Trial name
- ICONIC-LEAD (NCT06095115)
- Testing
- JNJ-77242113
- Where
- 170 sites in United States, Argentina and 14 more
- Volunteers
- 684 people
- Sponsor
- Janssen Research & Development, LLC
Moderate to Severe Psoriasis
Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy
Adalimumab has recently been authorized for active psoriasis in Peru and local experience is very low. The aim of this study is to obtain Peruvian data of clinical effectiveness and impact on health-related quality of life with…
- Trial name
- NCT01156532
- Where
- 3 sites in Peru
- Volunteers
- 30 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Moderate to Severe Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared with placebo.
- Trial name
- NCT05020249
- Testing
- bimekizumab
- Where
- 9 sites in South Korea
- Volunteers
- 47 people
- Sponsor
- UCB Biopharma SRL
Psoriasis
A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet
This is a Phase IV randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of SC efalizumab in adult patients (18 years of age and older) with chronic moderate to severe plaque psoriasis involving…
- Trial name
- NCT00312026
- Testing
- efalizumab
- Volunteers
- 75 people
- Sponsor
- Genentech, Inc.
Plaque Psoriasis
A Phase 3 Clinical Study of QL2106 Injection
It is a multicenter randomized, double-blinded, parallel, positive-controlled, Phase 3 comparative study to evaluate the efficacy and safety of QL2106 injection to Tremfya® in Patients with Moderate to Severe Plaque Psoriasis.
- Trial name
- NCT07511647
- Testing
- QL2106 injection, Tremfya®
- Where
- China
- Volunteers
- 318 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Moderate-to-severe Plaque Psoriasis
A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis
This is a multiple dose escalating and open labeled clinical trial to evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple subcutaneous (s.c.) injections of SHR-1314 in adults with moderate-to-severe plaque…
- Trial name
- NCT03710681
- Testing
- SHR-1314
- Where
- 2 sites in China
- Volunteers
- 16 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Psoriatic Arthritis
Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis
This is a Phase 2a study to investigate the efficacy, safety, tolerability, PK, and PD of ATI-450 versus placebo in patients with moderate to severe psoriatic arthritis.
- Trial name
- NCT05511519
- Testing
- ATI-450
- Where
- 22 sites in United States, Poland
- Volunteers
- 47 people
- Sponsor
- Aclaris Therapeutics, Inc.
Psoriasis
Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study is to determine the effectiveness and safety, over 12 weeks, of 3 dosing regimens of CP-690,550 for the treatment of adults with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT00678210
- Testing
- CP-690,550
- Where
- 44 sites in United States, Canada
- Volunteers
- 197 people
- Sponsor
- Pfizer